Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer

American Journal of Kidney Diseases

Volumn 42, Issue 2, 2003, Pages 342-349

  Sowinski, Kevin M ^a   Lucksiri, Aroonrut ^b   Kays, Michael B ^b   Scott, Meri K ^b   Mueller, Bruce A ^b   Hamburger, Richard J ^b  

^a PURDUE UNIVERSITY   (United States)

^b NONE

Author keywords

Hemodialysis (HD); Levofloxacin; Pharmacokinetics; Renal failure

Indexed keywords

CELLULOSE ACETATE; LEVOFLOXACIN;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DOSE REGIMEN; DRUG INFUSION; ENTEROBACTER CLOACAE; FEMALE; HAEMOPHILUS INFLUENZAE TYPE A; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; KLEBSIELLA; MALE; MINIMAL RESIDUAL DISEASE; MINIMUM INHIBITORY CONCENTRATION; MODEL; MORAXELLA CATARRHALIS; NONLINEAR SYSTEM; SPECIES COMPARISON;

EID: 0042627948     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00660-7     Document Type: Article

References (32)

1. US Renal Data System: USRDS 2001 Annual Data Report. The National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2001
2. Fish DN, Chow AT: The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32:101-119, 1997
3. Flor S, Guay D, Opsahl J, et al: Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment. Int J Clin Pharmacol Res 11:115-121, 1991
4. Bandai H, Tsubakihara Y, Yamato E, et al: Pharmacokinetics of ofloxacin in severe chronic renal failure. Clin Ther 11:210-218, 1989
5. Dorfler A, Schulz W, Burkhardt F, et al: Pharmacokinetics of ofloxacin in patients on haemodialysis treatment. Drugs 34:S62-S70, 1987 (suppl I)
6. Kampf D, Borner K, Pustelnik A: Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis. J Antimicrob Chemother 26:S61-S68, 1990 (suppl D)
7. White LO, MacGowan AP, Mackay IG, et al: The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure. J Antimicrob Chemother 22:S65-S72, 1988 (suppl C)
8. Lameire N, Rosenkranz B, Malerczyk V, et al: Ofloxacin pharmacokinetics in chronic renal failure and dialysis. Clin Pharmacokinet 21:357-371, 1991
9. Bellmann R, Egger P, Gritsch W, et al: Elimination of levofloxacin in critically ill patients with renal failure: Influence of continuous veno-venous hemofiltration. Int J Clin Pharmacol Ther 40:142-149, 2002
10. Guenter SG, Iven H, Boos C, et al: Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Pharmacotherapy 22:175-183, 2002
11. Hansen E, Bucher M, Jakob W, et al: Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. Intensive Care Med 27:371-375, 2001
12. Malone RS, Fish DN, Abraham E, et al: Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 45:2949-2954, 2001
13. Traunmuller F, Thalhammer-Scherrer R, Locker GJ, et al: Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. J Antimicrob Chemother 47:229-231, 2001
14. Kays MB, Overholser BR, Mueller BA, Moe S, Sowinski KM: Effect of sevelamer and calcium acetate on the relative oral bioavailability of ciprofloxacin. J Am Soc Nephrol 13:257A, 2002 (abstr)
15. Liang H, Kays MB, Sowinski KM: Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: Application to levofloxacin determination in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 772:53-63, 2002
16. Scott MK, Mueller BA, Sowinski KM: The effects of peracetic acid-hydrogen peroxide reprocessing on dialyzer solute and water permeability. Pharmacotherapy 19:1042-1049, 1999
17. D'Argenio DZ, Schumitzky A: Adapt II Release 4, User's Guide, Los Angeles, CA, Biomedical Simulations Resource. University of Southern California, 1997
18. Schaedeli F, Uehlinger DE: Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis. Clin Pharmacol Ther 63:26-38, 1998
19. Sowinski KM, Mueller BA, Grabe DW, et al: Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis 37:766-776, 2001
20. Spivey JM, Blum RA, Nix DE: Mathematic modeling of drug disposition and postdialysis rebound in patients requiring hemodialysis. Pharmacotherapy 12:201-206, 1992
21. DeSoi CA, Sahm DF, Umans JG: Vancomycin elimination during high-flux hemodialysis: Kinetic model and comparison of four membranes. Am J Kidney Dis 20:354-360, 1992
22. Daugirdas JT: Second-generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol 4:1205-1213, 1993
23. Watson PE, Watson ID, Batt RD: Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 33:27-39, 1980
24. Thornsberry C, Jones ME, Hickey ML, et al: Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother 44:749-759, 1999
25. Hoban DJ, Bouchillon SK, Johnson JL, et al: Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn Microbiol Infect Dis 40:51-57, 2001
26. Ortho-McNeil Pharmaceutical Inc: Levaquin Package insert. Raritan, NJ, Ortho-McNeil Pharmaceutical Inc, 2002
27. Aronoff GR, Berns JS, Brier ME, et al: Drug Prescribing in Renal Failure (ed 4). Philadelphia, PA, American College of Physicians, 1999
28. Craig WA: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12, 1998
29. Preston SL, Drusano GL, Berman AL, et al: Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 279:125-129, 1998
30. Forrest A, Nix DE, Ballow CH, et al: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073-1081, 1993
31. Klepser ME, Ernst EJ, Petzold CR, et al: Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 45:673-678, 2001
32. Thalhammer F, Kietzmayr J, El Menyawi I, et al: Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers. Am J Kidney Dis 32:642-645, 1998